Press Releases

Context Therapeutics Inc, a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. (“Link”), a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody with first-in-class potential that has received Investigational New Drug (“IND”) clearance from the U.S. Food and

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced positive results from Parts A and B of its Phase 1 clinical trial of SKY-0515, which is being developed as a potential treatment for Huntington’s disease (HD). SKY-0515 demonstrated an average HTT mRNA reduction of 72% at a daily oral dose of 9mg and was generally well tolerated at all doses tested. SKY-0515 is

AzarGen Biotechnologies, specializing in plant-based biomanufacturing, presents a series of tailor-made synthetic promoters with superior performance compared to ‘benchmark’ promoters such as the Cauliflower Mosaic Virus (CaMV) 35S promoter and the RuBisCo small subunit promoter. AZprom™ shows a dramatic increase in the expression of fluorescent proteins, outperforming the ‘double-enhancer’ CaMV 35S promoter more than 5-fold in transgenic tobacco plants

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into an exclusivity and right of first offer agreement (the “Agreement”) with TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Pursuant to the Agreement, among ot

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil® (remestemcel-L) in the treatment of children with SR-aGVHD. The filing comes after Mesoblast was informed by FDA at the end of March that, following additional consideration, the available clinical data from the Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed BLA for remestemcel-L for t

Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth. Additional new investors British Patient Capital (a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank), Can

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), and other diseases with significant unmet medical need, today announced an update on its clinical program evaluating lanifibranor for the treatment of MASH/NASH and its financial position. Fr&eacut

Roche announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) a

Rune Labs, a leader in precision medicine for Parkinson’s disease, celebrates the signing of the National Plan to End Parkinson's Disease into law. This landmark legislation aims to unite federal and philanthropic efforts to diagnose and treat Parkinson’s Disease, helping to ensure access to necessary care for American families. Brian Pepin, CEO of Rune Labs, expressed his enthusiasm: "The signing of the National Plan to End Parkinson's Disease into law is a

GB Sciences, Inc., a leading plant-inspired biopharmaceutical research and development company, has signed a letter of intent outlining terms for a licensing deal with Endopure Life Sciences, LLC, a company with experience in manufacturing and supplying cannabinoid-based treatments to the regulated markets of Brazil and within South America. GB Sciences is licensing a suite of cannabinoid-based treatments for neurological disorders to Endopure Life Sciences. Aging populations have caused incr